Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL841799 | 0.98 | ATM (0.65) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL9416002 | 0.85 | ATM (0.63) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL21346316 | 0.84 | ALDH1A1 (0.62) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL31113981 | 0.84 | ALDH1A1 (0.62) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL4901405 | 0.84 | L3MBTL1 (0.61) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL23330757 | 0.84 | ATM (0.49) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL12000676 | 0.83 | TACR1 (0.48) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL3670110 | 0.82 | ATM (0.73) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL21346095 | 0.82 | HTR2A (0.49) | ATML3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL3670113 | 0.82 | ATM (0.73) | ATML3MBTL1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023070228-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE CANADA INC. (CA) | 2023-05-04 | — | — | WO | disclosed |
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| EP-2907514-B1 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2019-10-23 | — | — | EP | disclosed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-20170298090-A1 | Modulators of ROR-gamma Receptors, Composition and Use Thereof | KULING THERAPEUTICS (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20170298090-A1 | Modulators of ROR-gamma Receptors, Composition and Use Thereof | KULING THERAPEUTICS (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| EP-2042173-A2 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | ATM 719/4885L3MBTL1 2080/4885ALDH1A1 3857/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | ATM 1162/4885L3MBTL1 2441/4885ALDH1A1 961/4885 |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | HTR2C, HTR2A, HTR3B | ATM 2283/4885L3MBTL1 1463/4885ALDH1A1 2466/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | ATM 4782/4885L3MBTL1 769/4885ALDH1A1 1424/4885 |
| US-10561661-B2 | Purine derivative compounds for medical use | MSR1, TPMT, M6PR | ATM 2759/4885L3MBTL1 713/4885ALDH1A1 1826/4885 |
| US-20170298090-A1 | Modulators of ROR-gamma Receptors, Composition and Use Thereof | RORC, RORB, RORA | ATM 4874/4885L3MBTL1 4210/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.